Skip to main
OBIO

OBIO Stock Forecast & Price Target

OBIO Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Orchestra BioMed Holdings Inc. demonstrates a robust investment in its growth through increased expenditures, with SG&A expenses rising by 12% year-over-year to $26.9 million, reflecting its commitment to enhancing operational capabilities. The company's R&D expenditures have also surged, climbing 21% year-over-year to reach $14 million, and projected R&D expenses of $58.2 million for 2025 signal a strong focus on the development of innovative therapies. This strategic emphasis on research and development, paired with risk-reward sharing partnerships, positions the company favorably for successful penetration into targeted markets and potential future revenue growth.

Bears say

Orchestra BioMed Holdings Inc. has consistently reported operating losses since its inception, indicating a lack of financial stability. This ongoing trend of negative financial performance raises concerns about the company’s ability to achieve and sustain profitability in the future. Given these factors, the company's financial outlook remains challenging, with significant risks associated with its business model and developmental stage.

OBIO has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orchestra BioMed Holdings Inc (OBIO) Forecast

Analysts have given OBIO a Strong Buy based on their latest research and market trends.

According to 4 analysts, OBIO has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orchestra BioMed Holdings Inc (OBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.